Jakavi 25mg (Ruxolitinib)
Jakavi 25mg belongs to type of targeted therapy which performs as oral receptor tyrosine kinase inhibitor
Jakavi 25mg also an ATP-competitive inhibitor of JAK1 and JAK2 and prohibition resulted regardless of the JAK2V617F mutational status.
Jakavi 25mg is prescription drug provided under supervision of
Jakavi 25mg is indicated for the treatment in patients with intermediate and high-risk myelofibrosis.
Mechanism of action
Ruxolitinib belongs to a type of drug called a protein kinase inhibitor.
Genes known as JAK1 and JAK2 help regulate the number of blood cells the body makes. If either of these genes become damaged, the body may make more blood cells. Ruxolitinib inhibits the indication that are sent by the damaged gene. This helps decrease the number of extra blood cells which are made.
Ruxolitinib can stop other signs that cause more blood cells to be made. So, it can also work for people who do not have a damaged JAK gene.
Absorption: fast absorption and not affected by food maximum plasma level is 1.5 hours.
Distribution: volume of distribution is 76.6 L plasma protein binding is
Metabolism: metabolized by CYP3A4
Elimination: excreted through urine 74% and unchanged drug is <1% and through urine 22% , <1 % as unchanged drug
Dosage and administration
Starting recommended doses for myelofibrosis
If Platelet count >200 x10^9/L the prescribed dose is 20 mg PO BID
If Platelet count 100-200 x10^9/L the prescribed dose is 15 mg PO BID
If Platelet count 50 to <100 x10^9/L the prescribed dose is 5 mg PO BID
Titrate dose based on response; not to exceed 25 mg PO BID
The prescribed dose is 10mg PO BID
Undergo CBC and platelet count prior starting and q2-4wk until doses are stabilized, and then as clinically used.
Common side effects caused due to Jakavi 25mg
Serious side effects caused due to Jakavi 25mg
- High Cholesterol level
- Nausea & Vomiting
- raised in liver enzymes
Concomitant use with fluconazole doses greater than 200mg daily may increase Ruxolitinib exposure leads to increase the risks of exposure related adverse reaction.
Concomitant use of Jakavi 25mg with strong CYP3A4 inhibitors will increases Ruxolitinib exposure.
Concomitant use of Jakavi 25mg with strong CYP3A4 inducers will decreases Ruxolitinib exposure.
Therapy with Jakavi 25mg can resulted in thrombocytopenia, Anemia and neutropenia. Regulate thrombocytopenia by reducing the dose or temporarily inhibit Jakavi 25mg. Platelet transfusions may be required.
Risk of infection occurs by delay initiate treatment with Jakavi 25mg until active severe infection have resolved.
The drug has no studies with the Jakavi 25mg use in pregnant women to inform drug-along with risks. Hence avoid becoming pregnancy during Jakavi 25mg treatment
Do not breast feed to infants during treatment with Jakavi 25mg. Excretion into human milk is unknown
Jakavi 25mg stored at 200C to 250C
Protect away from light and moisture
Dispense in its original container
If dose is forgot, then have the dose immediately before next dose timing reaches or skip the missed dose and follow the regular schedule.
Discuss with doctors regarding missed dose.
- Trade name Jakavi 25mg
- Substance Ruxolitinib
- Manufacturer Novartis ltd
- Packaging 60 tablets
- Country of origin India